Biotech

All Articles

Lykos will inquire FDA to reassess its own choice observing being rejected of MDMA therapy for trauma

.Complying with an inadequate revealing for Lykos Rehabs' MDMA applicant for trauma at a recent FDA ...

AN 2 halves headcount, quits phase 3 trial after information dissatisfy

.AN2 Rehabs is actually reviewing its own business in response to uninspired midphase records, pledg...

Merck pays out $700M for bispecific, spying autoimmune position and odds to test Amgen in cancer cells

.Merck &amp Co. is paying out $700 thousand upfront to test Amgen in a blood stream cancer market. T...

Gilead spends J&ampJ $320M to exit licensing package for seladelpar

.With Gilead Sciences about to an FDA choice for its own liver health condition medicine seladelpar,...

' All palms on deck' at Lilly as peers target obesity market

.CEO David Ricks can see the firms establishing tents at basecamp behind Eli Lilly in an effort to r...

Entero laying off workers, abandoning workplace as well as pausing R&ampD

.Bed Liquidators has actually transformed Entero Rehabs white colored as a sheet. The financial inst...

Exelixis loses ADC after choosing it is actually no match for Tivdak

.Exelixis is quiting on its tissue element (TF)- targeting antibody-drug conjugate after wrapping up...

Relay dislikes SHP2 inhibitor after Genentech leaves

.Three full weeks after Roche's Genentech device walked away from an SHP2 prevention deal, Relay The...

Stoke's Dravet disorder med released of predisposed scientific grip

.Stoke Rehabs' Dravet syndrome medicine has actually been actually devoid of a predisposed grip, cle...

Fierce Biotech's Gabrielle Masson presents Fierce 15 at NYSE

.Intense Biotech Partner Editor Gabrielle Masson offered the 2024 training class of Fierce 15 winner...